Modes of resistance to anti-angiogenic therapy

@article{Bergers2008ModesOR,
  title={Modes of resistance to anti-angiogenic therapy},
  author={G. Bergers and D. Hanahan},
  journal={Nature Reviews Cancer},
  year={2008},
  volume={8},
  pages={592-603}
}
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance… Expand
Understanding and targeting resistance to anti-angiogenic therapies.
TLDR
The purpose of this review is to detail the preclinical evidence for mechanisms of angiogenic resistance and provide an overview of novel therapeutic approaches exploiting these pathways. Expand
Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
  • A. Close
  • Biology, Medicine
  • Future medicinal chemistry
  • 2016
TLDR
The challenges and strategies for optimization of combination therapies including metronomic administration of drugs and the need for suitable prognostic and surrogate response biomarkers are discussed. Expand
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
TLDR
Different mechanisms involved in resistance to antiangiogenic therapies from early stage resistance involving mainly tumor cells to late stages related to the adaptation of the microenvironment are focused on. Expand
Role of the tumor stroma in resistance to anti-angiogenic therapy.
TLDR
The role of stromal cells in the resistance to anti-angiogenic drugs is described and possible strategies to overcome resistance and enhance the efficacy of angiostatic therapy are discussed. Expand
Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences.
A capacity for neoangiogenesis is a fundamental property of cancer (1,2). With the clinical application of multiple inhibitors of vascular endothelial growth factor (VEGF) signaling, angiogenesis isExpand
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
  • A. Rapisarda, G. Melillo
  • Medicine
  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2009
TLDR
The role of intra-tumor hypoxia as a mechanism of resistance to anti-angiogenic agents and speculates on therapeutic approaches that might circumvent resistance and thereby improve clinical outcome are focused on. Expand
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.
TLDR
An update on recent mechanisms via which tumor and stromal cells induce resistance is provided and recent evolutions in the (pre-clinical development of novel third-generation anti-angiogenic agents to overcome this problem are discussed. Expand
Resistance to Inhibitors of Angiogenesis
TLDR
The molecular and cellular mechanisms contributing to therapy resistance as well as possible strategies to improve the clinical outcome are discussed. Expand
Mechanisms of resistance to antiangiogenesis therapy.
TLDR
The theoretical benefits of VEGF inhibitors are more likely to be realised by understanding these mechanisms and modifying therapy accordingly, and the therapeutic implications are reviewed. Expand
Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
TLDR
A review of the mechanisms of resistance to anti-VEGF therapy and the postulated strategies to optimize antiangiogenic therapy discusses a number of multitargeted tyrosine kinase inhibitors currently in phase III clinical development. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 112 REFERENCES
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
When first conceived, antiangiogenic therapy for cancer offered the possibility of universal efficacy, low toxicity, and little possibility of resistance. Blockade of the vascular endothelial growthExpand
VEGF-targeted therapy: mechanisms of anti-tumour activity
Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as single agents or in combination with chemotherapy, have been shown to benefit patients with advanced-stageExpand
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors inExpand
Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed.
There is a large family of known pro-angiogenic growth factors, many of which can be expressed by a single tumor, especially in advanced stages of disease. Such redundancy, which can be amplified byExpand
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
TLDR
Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis, finding phenotypic resistance to V EGFR2 blockade emerged. Expand
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
The ultimate target of anti-angiogenic drugs is the genetically stable, activated endothelial cell of a newly forming tumor blood vessel, rather than the genetically unstable tumor cell populationExpand
Antiangiogenic therapy for cancer: current and emerging concepts.
TLDR
Current and emerging concepts of the mechanism of action of antiangiogenic therapies are reviewed and the implications of these mechanisms for their optimal clinical use are discussed. Expand
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents
  • R. Kerbel
  • Biology, Medicine
  • BioEssays : news and reviews in molecular, cellular and developmental biology
  • 1991
TLDR
It is argued that anti‐cancer strategies should be directed at eliminating those genetically stable normal diploid cells that are required for the progressive growth of tumors, and micro‐vascular endothelial cells comprising the tumor vasculature represent such a normal cell target. Expand
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
TLDR
The function of VEGF in normal and tumour angiogenesis is described, the rationale behind the use of anti-VEGF therapy in MBC is explored, and the therapeutic impact of such agents on tumour vasculature is detailed. Expand
Antiangiogenic Therapy for Cancer: An Update
TLDR
Clinical progress in targeting one of the major regulators of angiogenesis, vascular endothelial growth factor-A, is focused on and some recent advances in the elucidation of potential cellular and molecular mechanisms underlying refractoriness or resistance to antiangiogenic therapies are discussed. Expand
...
1
2
3
4
5
...